BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Everyday Seasonal Positions That Compensate Fairly in the US - 2Czech Republic's new premier: No money for Ukraine
- 3I took my shoes off and went for a barefoot hike. I couldn’t believe what happened next
- 4The most effective method to Pick a Campervan That Offers Something else for Less
- 5Traveling Alone: An Excursion of Self-Disclosure
- Must-Have Cooking Machine in Your Kitchen
- Greece eyes migrant repatriation centres outside the EU
- Paul Feig loves a plot twist. Why not reboot 'Die Hard' starring a woman?
- Creative Do-It-Yourself Ventures for Each Expertise Level
- Vote In favor of Your Favored Language Learning Applications
- The many ways that baking is winter therapy. With a delicious ending
- The Solution to Defeating Tarrying: Systems for Expanded Efficiency
- Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality
- Going with Children: Tips for Tranquil Family Get-aways
